Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents’ Search and Development

Abstract

Taking into account that the imidazole ring has π-electron redundancy, condensed benzimidazole derivatives have attracted our attention as a promising class for the search for antioxidant substances. Synthesis was carried out, and information on the antioxidant activity of imidazo-and tetrahydropyrimido benzimidazoles was provided. Highly active antioxidant substance enoxifol has been revealed. The data on the synthesis and study of the pharmacodynamic, pharmacokinetic, and toxicological properties of the new antioxidant compound enoxifol are presented. The antioxidant activity of the compound is due to its ability to inactivate superoxide, hydroxyl, and peroxyl radicals, thereby reducing the overall oxidation rate due to a decrease in the total initiation rate. It has been shown that enoxifol has hepatoprotector, antihypoxic, cerebroprotective, nootropic, stressprotective, neuropsychotropic, actoprotective, cardioprotective, antiaggregant, and antithrombogenic properties and is able to prevent rheological disorders in diabetes mellitus.

New 1H-benzimidazole-2-yl hydrazones with combined antiparasitic and antioxidant activity

“…The benzimidazoles are a large chemical family widely used in veterinary and human medicine to treat helminthic infections 13 and an appropriate structural platform for antioxidant discovery efforts. 14 In examining the recent literature, certain fragments were observed in the structure of benzimidazole-based antioxidants – a benzimidazole core, phenolic hydroxyl and/or methoxyl groups and hydrazone moiety ( Fig. 1 ).…”

Antitrombotic Activity of a New Benzimidazole Derivative With a Spatially Difficult Phenolic Substitute in Its Structure

“…В ходе ранее проведенных исследований, среди гетероциклических соединений были выявлены вещества, проявляющие антиагрегантные и антиоксидантные свойства [11][12][13]. Соединение под шифром РУ-1144 (1-(2,6-дитретбутил-4-(1-гидроксиэтил)-фенил-пиримидобензимидазолгидрохлорид), способно ингибировать процессы агрегации тромбоцитов и перекисного окисления липидов, превосходя препараты сравнения ацетилсалициловую кислоту, клопидогрел и этилметилгидроксипиридина сукцинат [31].…”